ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral William J. Crowe Jr. My thoughts are with his family during this difficult time,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions.
“A benevolent and courageous public servant, Admiral Crowe committed his life to serving the nation. He was a candid man who led with nobility and grace, and never wavered in his commitment to the protection of our country. His compassion and boundless love for his family and friends were matched only by his steadfast integrity and tenacious commitment to the United States military and the field of education. Admiral Crowe’s countless contributions to the American people will not be forgotten, and our nation is fortunate to have known such a dignitary. The Admiral was an invaluable asset to our company, and I will always remember the great strategic insight and disarming humor he brought to every situation. Emergent BioSolutions is a stronger company as a result of his vision and leadership, and I am particularly grateful for his many years of friendship,” he concluded.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.
Related posts:
- Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS)...
- Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James...
- EMERGENT BIOSOLUTIONS ANTICIPATES 2ND QUARTER BIOTHRAX REVENUES OF APPROXIMATELY $20 MILLION BASED ON ACCELERATED DELIVERY TO DEPARTMENT OF DEFENSE ROCKVILLE, MD, June 27, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a...
Related posts brought to you by Yet Another Related Posts Plugin.
